milatuzumab   Click here for help

GtoPdb Ligand ID: 8267

Synonyms: hLL1 | IMMU-115
Immunopharmacology Ligand
Compound class: Antibody
Comment: Milatuzumab is a humanized monoclonal antibody targeting CD74, a cell surface molecule which links the innate and adaptive immune responses by regulating the survival of macrophages and B cells. CD74 is also known as the invariant chain of major histocompatibility complex class II and acts as a receptor for macrophage migration inhibitory factor (MIF).
Milatuzumab may also be conjugated with doxorubicin creating the antibody-drug conjugate (ADC) hLL1-DOX (aka IMMU-110) [1].
Peptide sequence information for this antibody is available from its IMGT/mAb-DB link.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Both the FDA and EMA have granted milatuzumab orphan designation for the treatment of the rare diseases multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). Phase 2 clinical trials of milatuzumab for MM and CLL have been completed. A Phase 1/II study of hLL1-DOX for relapsed non-Hodgkin's lymphoma and CLL is ongoing (NCT01585688).
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Milatuzumab is rapidly internalised following binding to CD74 on the surface of malignant B cells, and this ultimately leads to apoptotic cell death [2].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01585688 Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL Phase 1/Phase 2 Interventional Immunomedics, Inc.